Yabao Pharmaceutical Group600351.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Yabao Pharmaceutical Group (600351.SH) trades at a P/E of 14.60x, P/B of 1.68x, P/S of 2.07x, and a dividend yield of 5.12%.
Longitudinal percentile comparison: P/E sits at the 8th percentile over the trailing 10Y window (vs. 24th percentile over 3Y); P/B sits at the 55th percentile over the trailing 10Y window (vs. 77th percentile over 3Y); P/S sits at the 74th percentile over the trailing 10Y window (vs. 84th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 8th percentile within its industry and the 13th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 7.43%, ranking at the 91st percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 46.1 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 5.12% comes from cash dividends, with an implied ~2.32% from buybacks — a fairly balanced mix of both channels. Yabao Pharmaceutical Group operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 600351 · SSE: 600351 · 600351
Want the full picture on whether Yabao Pharmaceutical Group (600351.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 14.60 | ||||||
| P/B (MRQ) | 1.68 | ||||||
| P/S (TTM) | 2.07 | ||||||
| Dividend Yield | 5.12% | ||||||
| Buyback + Div Yield | 7.43% |